Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

These 52-week data highlight bimekizumab’s efficacy in the scalp, nail, and genital region for psoriasis, along with Dermatology Life Quality Index (DLQI) improvements.

Study Finds Bimekizumab Improves Genital, Scalp, Nail Psoriasis at 52 Weeks

This pooled analysis of 3-year data yielded positive efficacy and safety findings for deucravacitinib treatment of those with psoriasis. 

Deucravacitinib Safe, Effective Through 3 Years for Patients with Psoriasis

Two supplemental Biologics License Applications for guselkumab were submitted to the FDA for treatment of children with plaque psoriasis and active juvenile psoriatic arthritis.

FDA Receives sBLA for Guselkumab Treatment of Psoriasis, Juvenile PsA in Adolescents

These findings indicate that incorporating educational video materials for psoriasis improved engagement in the shared decision-making process.

Educational Video Use in Shared Decision-Making Improves Literacy About Psoriasis

The investigators of this study noted an association between obesity and conditions such as rosacea, psoriasis, and lichen simplex chronicus.

Link Identified Between Obesity, Inflammatory Skin Diseases Such as Psoriasis

This study highlighted that both PASI scores and systemic inflammation, assessed using GlycA levels, were linked with cardiovascular disease.

Psoriasis Severity, Systemic Inflammation Associated with Cardiovascular Disease

These retrospective, 52-week data highlight the efficacy and safety of bimekizumab for those with moderate-to-severe psoriasis.

Long-Term Bimekizumab Treatment Shown to be Effective for Patients with Psoriasis

These data were announced by Protagonist Therapeutics, resulting from the 2 pivotal ICONIC-LEAD and ICONIC-TOTAL studies on the oral peptide icotrokinra.

Positive Phase 3 Results Announced for JNJ-2113 Treatment of Psoriasis

In this cross-sectional survey analysis, new insights were explored regarding clinical practice patterns and treatment outcomes within dermatology practices in the US.

Study Highlights Real-World Characteristics of Providers Treating Psoriasis in US

These results point to the value of awareness among physicians and patients of the risk of psoriasis linked to immunotherapy during cancer care.

Individuals with Cancer Treated with Immune Checkpoint Inhibitors at Risk for Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Plaque Psoriasis